Natixis Advisors LLC Buys 11,936 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Natixis Advisors LLC increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 54.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 33,982 shares of the medical research company’s stock after buying an additional 11,936 shares during the period. Natixis Advisors LLC’s holdings in NeoGenomics were worth $501,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Light Asset Management LLC raised its stake in NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after purchasing an additional 480,396 shares in the last quarter. Blue Trust Inc. raised its stake in NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares in the last quarter. Sei Investments Co. raised its stake in NeoGenomics by 152.6% in the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock worth $3,658,000 after purchasing an additional 159,350 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in NeoGenomics by 7.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after purchasing an additional 217,687 shares in the last quarter. Finally, Candriam S.C.A. raised its stake in NeoGenomics by 29.9% in the 2nd quarter. Candriam S.C.A. now owns 487,026 shares of the medical research company’s stock worth $6,755,000 after purchasing an additional 112,009 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on NEO. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Wednesday, November 6th. Benchmark reiterated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $20.25.

Insider Buying and Selling

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now directly owns 37,129 shares in the company, valued at $570,301.44. This represents a 12.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $17.74 on Friday. The firm has a 50 day moving average of $14.72 and a 200-day moving average of $14.89. The stock has a market capitalization of $2.28 billion, a PE ratio of -29.08 and a beta of 1.19. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc. has a 12 month low of $12.77 and a 12 month high of $21.22.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) EPS. On average, equities research analysts predict that NeoGenomics, Inc. will post -0.17 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.